SyntekaBio

SyntekaBio EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of SyntekaBio (226330.KQ) as of Nov 20, 2026 is -23.07. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -6.91 — a change of 233.87% (lower).

EV/EBITDA

-23.07

YoY

233.87%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of SyntekaBio is 2024 -23.07 . EV/EBITDA (Enterprise Value to EBITDA) of SyntekaBio was 2023 -6.91 . It decreases by 233.87% lower compared to the previous year.

The SyntekaBio EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2017
-14.24 KRW
Jan 1, 2018
17.43 KRW
Jan 1, 2019
-7.67 KRW
Jan 1, 2020
-6.38 KRW
Jan 1, 2021
-4.54 KRW
Jan 1, 2022
-4.17 KRW
Jan 1, 2023
-6.91 KRW
Jan 1, 2024
-23.07 KRW
The SyntekaBio EV/EBITDA history
YEAREV/EBITDAYoY
-23.07+233.87%
-6.91+65.65%
-4.17-8.14%
-4.54-28.83%
-6.38-16.85%
-7.67-144.02%
17.43-222.42%
-14.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

EV/EBITDA (Enterprise Value to EBITDA) of SyntekaBio is -23.07 in 2024.

EV/EBITDA (Enterprise Value to EBITDA) of SyntekaBio changed from -6.91 to -23.07, representing a 233.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s SyntekaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SyntekaBio

All Key Metrics — SyntekaBio